Algernon Pharmaceuticals Inc (OTCMKTS: BTHCF) CEO Christopher Moreau sat down with Proactive's Steve Darling at the 12th annual LD Micro Conference in Bel Air, California. The Vancouver, British Columbia-based clinical stage pharmaceutical development company is advancing its lead compounds for non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease and idiopathic pulmonary fibrosis.
0 Comments